Wedbush Boosts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $30.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective hoisted by equities researchers at Wedbush from $29.00 to $30.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective points to a potential upside of 181.69% from the stock’s previous close.

Several other brokerages also recently weighed in on DAWN. Piper Sandler increased their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. HC Wainwright decreased their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday. Finally, TD Cowen initiated coverage on shares of Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.14.

Day One Biopharmaceuticals Trading Down 2.6%

Shares of Day One Biopharmaceuticals stock opened at $10.65 on Wednesday. The firm’s 50 day simple moving average is $10.69 and its two-hundred day simple moving average is $8.77. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -10.34 and a beta of -1.26. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million for the quarter, compared to analysts’ expectations of $49.81 million. On average, sell-side analysts predict that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 15,459 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $179,324.40. Following the sale, the chief executive officer directly owned 204,603 shares in the company, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. The trade was a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 36,461 shares of company stock valued at $422,948 over the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DAWN. AIGH Capital Management LLC purchased a new position in shares of Day One Biopharmaceuticals during the third quarter worth about $10,719,000. AlphaQuest LLC grew its stake in Day One Biopharmaceuticals by 1,065.6% during the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock worth $1,304,000 after buying an additional 169,134 shares during the last quarter. Schroder Investment Management Group acquired a new position in Day One Biopharmaceuticals during the second quarter worth approximately $1,171,000. Geode Capital Management LLC lifted its stake in Day One Biopharmaceuticals by 11.2% in the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after buying an additional 171,964 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its stake in Day One Biopharmaceuticals by 71.7% in the second quarter. Dynamic Technology Lab Private Ltd now owns 83,223 shares of the company’s stock valued at $541,000 after buying an additional 34,766 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals News Summary

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.